Mirador Raises $250M Series B to Fuel Precision Immunology Pipeline…

Team S · 2026-01-13T13:20:33.000Z

Clinical-stage precision medicine company Mirador Therapeutics has closed a $250 million Series B funding round, significantly bolstering its efforts to develop next-generation treatments for immune-mediated inflammatory and fibrotic diseases including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and idiopathic pulmonary fibrosis. The financing round, which closed in Q3 2025, brings Mirador’s total capital raised to more than $650 million since its launch in March 2024, reflecting strong investor confidence in the company’s multi-asset clinical pipeline and strategic development platform. The new funds will be used to advance proof-of-concept across multiple clinical-stage assets and support the development of additional pipeline candidates. Mirador’s precision medicine engine, Mirador360™ (M360), leverages more than 2.5 million patient profiles combined with advanced machine learning to accelerate target discovery, patient stratification and indication expansion enabling the company to move toward 10 or more clinical readouts by year-end 2027. CEO Mark C. McKenna says the company’s strategy focuses on novel targets, rational combinations and multi-specific therapies to overcome the limitations of current treatments in immuno-fibrotic disease. The Series B round attracted new investment from funds and accounts advised by T. Rowe Price Investment Management, Inc., Adage Capital Partners L.P., and additional funds managed by Fidelity Management & Research Company, alongside substantial participation from previous backers. Returning investors include ARCH Venture Partners, OrbiMed, Fairmount, Point72, Farallon Capital Management, Boxer Capital, TCGX, Invus, Logos Capital, Moore Strategic Ventures, Blue Owl Healthcare Opportunities, Woodline Partners LP and Venrock Healthcare Capital Partners, as well as several undisclosed participants highlighting a broad base of support across leading life sciences and venture investors. Mirador’s expanded Series B financing boosts the company’s ability to accelerate clinical development across its portfolio and underscores a larger industry shift toward precision immunology and inflammation therapy innovation. With a robust technological foundation and deep capital backing, Mirador is positioned to become a major player in immunology as it drives therapies from discovery through clinical validation. #MiradorTherapeutics, #SeriesBFunding, #PrecisionMedicine, #Immunology, #InflammationTherapies, #BiotechFunding, #ClinicalPipeline, #HealthcareInnovation, #LifeSciences, #AIinMed, #BiotechInvesting

Member Login Get Access

Mirador Raises $250M Series B to Fuel Precision Immunology Pipeline… | Newnex